Breaking Finance News

Bayer (ETR:BAYN) price target upped to 118.00EUR, released a research note earlier today by equinet AG

equinet AG increased the stock price target of Bayer (ETR:BAYN) to 118.00EUR reporting a possible upside of 0.12%.

Previously on 2/09/2017, equinet AG reported on Bayer (ETR:BAYN) bumped up the target price from 0.00EUR to 118.00EUR that indicated a possible upside of 0.12%.

Yesterday Bayer (ETR:BAYN) traded 0.00% even at 105.40EUR. The company’s 50-day moving average is 0.04EUR and its 200-day moving average is 0.03EUR. The last stock close price is up -69.79% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.06% over the same period. Trade Volume was down over the average, with 0 shares of BAYN changing hands under the typical 211

See Chart Below

Bayer (ETR:BAYN)

Bayer has a 52 week low of 0.01EUR and a 52 week high of 0.08EUR Bayer’s market capitalization is currently 0 EUR.

Brief Synopsis On Bayer (ETR:BAYN)

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical intermediates.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.